Pharma News

The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Gilead Sciences’ stock is up 12% this year, topping a 1% gain for the NYSE Arca Pharmaceutical Index.  Chief Executives don’t usually brag about paying high tax rates.

Ipsen’s elafibranor (sold under the brand name Iqirvo) has shown promise as a treatment for primary sclerosing cholangitis (PSC),

Eli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical Histrory

Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination

Thermo Fisher Scientific to invest $2bn into US manufacturing capabilities

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

Equillium Announces Feedback from the U.S. Food and Drug Administration

Veraxa to go public in $1.6bn SPAC deal with Voyager

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research

FDA Approves Digital Therapeutic for Migraine, Phase 1 Study of AMX0114 in ALS Begins

LEO Pharma and the Parker Institute at Copenhagen University Hospital have entered into a three-year academic partnership aimed at advancing dermatology research.